Synonyms: CNTO-1275 | L04AC05 | Stelara® | TT-20
ustekinumab is an approved drug (FDA (2009), EMA (2009))
Compound class:
Antibody
Comment: Ustekinumab suppresses the immunomodulatory actions of both IL-12 and IL-23 on T-cell sub-populations. It binds to the common p40 subunit (IL12B) shared by these cytokines.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Qyuns Therapeutics have a potential ustekinumab biosimilar (QX001S) in Phase 1 evaluation for psoriasis (trial registry number ChiCTR1900022127). |
No information available. |
External links ![]() |
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA) |